Clinical Trial

Saxenda: Underlying Mechanisms and Clinical Outcomes

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2016-10-24; most recent amendment 2026-04-27.
Status change: Recruiting → Active, Not Recruiting 2019-04-05
Status change: Not Yet Recruiting → Recruiting 2017-01-05
Trial Details
NCT Number NCT02944500
Lead Sponsor Beth Israel Deaconess Medical Center
Conditions Obesity
Enrollment 28 participants
Start Date 2016-11
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-01